Verastem Pegs Pro Forma Cash At $422.8 Million, With Runway Into First Half Of 2028

The company says cash plus expected product revenue should last into the first half of 2028, as it lays out 2026-2027 trial milestones.

Share
Verastem Pegs Pro Forma Cash At $422.8 Million, With Runway Into First Half Of 2028

Verastem, which develops cancer drugs aimed at tumors driven by the RAS/MAPK pathway, put its pro forma cash at $422.8 million in a corporate presentation furnished Thursday. The company says that cash, combined with expected product revenue, should extend its runway into the first half of 2028.

From $172.8 million to $422.8 million

The pro forma figure counts cash, equivalents and short-term investments as of September 30 plus $250.0 million in gross proceeds from the October public offering. Without that raise, the balance on September 30 was $172.8 million.

Third-quarter net product revenue from AVMAPKI FAKZYNJA CO-PACK was $24.0 million. GAAP operating expenses for the quarter were $99.2 million, and the company's adjusted operating expenses were $95.2 million.

Shares outstanding were 94.5 million at September 30, excluding 9.7 million shares that unexercised pre-funded warrants could add.

The deck also lists an Oberland revenue-note facility of up to $75 million. Of that, $50 million was funded at closing in August 2026, and the remaining $25 million is available at the company's option if quarterly sales of the product reach at least $40 million by the first quarter of 2027. The notes carry no financial covenants.

The ovarian product and a KRAS G12D drug

The company's marketed medicine combines avutometinib and defactinib for adults with KRAS-mutated recurrent low-grade serous ovarian cancer. The deck says demand held steady in the third quarter after significant growth in the second.

The FDA has granted priority review to a blister-pack version of the product, with a target decision date of February 7, 2027. The company also expects topline results from its Phase 3 confirmatory trial, RAMP 301, by mid-2027.

The second bet is VS-7375, an oral KRAS G12D inhibitor the company calls a potential best-in-class treatment. Data in the deck, which the company first reported in an October 14 filing, include a 41% confirmed response rate in previously treated pancreatic cancer.

A crowded trial calendar

Fourth-quarter 2026 targets include opening TARGET-D 301, a Phase 3 trial in first-line pancreatic cancer, completing enrollment in two Phase 2 trials (pancreatic and colorectal), and meeting the FDA on Phase 3 designs for first-line lung and colorectal cancer.

In 2027, the company plans mature colorectal data in the first quarter and initial data from the second-line pancreatic trial and a first-line pancreatic combination in the second quarter. It also plans to complete enrollment in the lung trial in the second quarter and report initial lung and second-line colorectal data in the second half. The deck marks some of these results as intended for a medical meeting.

Management is scheduled to present at investor conferences on November 9, November 10 and November 16.

Sources

More on Verastem

All Verastem (VSTM) coverage →